Tap­ping Chi­nese in­vestors, Apex­i­gen clos­es $73M for 8 tri­als in I/O

Apex­i­gen, a small com­pa­ny in Cal­i­for­nia, just closed a cou­ple rounds of cash to­tal­ing $73 mil­lion — most­ly from Chi­nese in­vestors — to push for­ward a slew of im­muno-on­col­o­gy pro­grams.

The com­pa­ny is us­ing the cap­i­tal to ad­vance its lead prod­uct can­di­date called APX005M, a mon­o­clon­al an­ti­body tar­get­ing CD40. Apex­i­gen is al­ready in sev­er­al Phase II stud­ies on the drug, test­ing dif­fer­ent types of can­cer in­clud­ing melanoma, non-small cell lung can­cer, pan­cre­at­ic can­cer and re­nal cell car­ci­no­ma in var­i­ous com­bos with im­munother­a­py, chemother­a­py or ra­di­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.